Abstract: Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.

Abstract: Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.

Abstract: Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.

Abstract: The signal converter of the present invention receives a multichannel video signal and converts the video signal into a microwave signal, the phase of which has been modulated with the video signal. The signal converter includes: a laser light source; a modulating section for modulating the phase of output light of the laser light source with the multichannel video signal and modulating the intensity of the output light with the microwave signal; and a light receiver for receiving the output light modulated by the modulating section and for outputting the microwave signal, the phase of which has been modulated with the multichannel video signal.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1-C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1-C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl), oxazolidinyl (which may be substituted with one or two C1-C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1-C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I wherein X represents nitrogen atom or CH; R1 represents halogen atom or hydroxyl; R2 represents hydrogen atom, hydroxyl or amino; R3 represents morpholino (which may be substituted with one or two C1–C6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl) or NR6R7 [R6 represents C1–C6 alkyl and R7 represents piperidinyl (which may be substituted with C1–C6 alkyl)]; R4 and R5 each represents hydrogen atom or C1–C6 alkyl, with the proviso that R2 is hydrogen atom and R3 is pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl) when R1 is hydroxyl

Abstract: Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1–C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1–C6 alkyl, C2–C6 alkenyl, C3–C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1–C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1–C6 alkyl, C2–C6 alkenyl, C3–C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1–C6 alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1-C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1-C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl), oxazolidinyl (which may be substituted with one or two C1-C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1-C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.

Abstract: Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1–C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1–C6 alkyl or C1–C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1–C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl), oxazolidinyl (which may be substituted with one or two C1–C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1–C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I wherein X represents nitrogen atom or CH; R1 represents halogen atom or hydroxyl; R2 represents hydrogen atom, hydroxyl or amino; R3 represents morpholino (which may be substituted with one or two C1-C6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl) or NR6R7 [R6 represents C1-C6 alkyl and R7 represents piperidinyl (which may be substituted with C1-C6 alkyl)]; R4 and R5 each represents hydrogen atom or C1-C6 alkyl, with the proviso that R2 is hydrogen atom and R3 is pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl) when R1 is hydroxyl

Abstract: A cephem compound or pharmaceutically acceptable salt thereof represented by the formula I: wherein R1 and R2 may be the same or different and each represent hydrogen atom, nitro or cyano; R3 represents C1-C6 alkyl which may be substituted with carboxyl; R4 represents hydrogen atom or amino; X represents —S— or —SO—, there being no case where both of R1 and R2 are simultaneously hydrogen atom.

Abstract: The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: 1

Abstract: Heterocyclic compound represented by the formula I 1

Abstract: A cephem compound or pharmaceutically acceptable salt thereof represented by the formula I: 1

Abstract: The signal converter of the present invention receives a multichannel video signal and converts the video signal into a microwave signal, the phase of which has been modulated with the video signal. The signal converter includes: a laser light source; a modulating section for modulating the phase of output light of the laser light source with the multichannel video signal and modulating the intensity of the output light with the microwave signal; and a light receiver for receiving the output light modulated by the modulating section and for outputting the microwave signal, the phase of which has been modulated with the multichannel video signal.

Abstract: Azaindolizinon derivatives or pharmaceutically acceptable salts thereof represented by the formula I: wherein R1 represents hydrogen atom, halogen atom or C1-C6 alkyl, R2 represents hydrogen atom, C1-C6 alkyl, C1-C6alkoxy, hydroxy, halogen atom, amino, acetylamino, benzylamino, trifluoromethyl or —O—(CH2)n—R5 (R5 represents vinyl, C3-C8 cycloalkyl or phenyl, n being 0 or 1), R3 and R4 respectively represent C1-C6 alkyl or —CH(R7)—R6 (wherein R6 represents vinyl, ethynyl, phenyl (which may be substituted with C1-C6 alkyl, C1-C6 alkoxy, hydroxy, one or two halogen atoms, di C1-C6 alkylamino, cyano, nitro, carboxy or phenyl), phenethyl, pyridyl, thienyl or furyl and R7 represents hydrogen atom or C1-C6 alkyl) or R3 is coupled with R4 to form indan or dihydrophenalene.

Abstract: Disclosed is a wavelength multiplexing/demultiplexing optical transfer system which is prevented from becoming larger by an increase in the number of wavelength multiplexing/demultiplexing couplers which is increased as the number of wavelengths increases, thereby reducing the number of assembling steps to lead to cost reduction. As WDM (Wavelength Division Multiplexing) optical receiver modules each having a wavelength multiplexing/demultiplexing element and a light emitting element are connected sequentially, an input optical signal with four wavelengths is demultiplexed and each demultiplexed signal is converted to an electric signal to thereby ensure wavelength demultiplexing and data reproduction.

Abstract: The signal converter of the present invention receives a multichannel video signal and converts the video signal into a microwave signal, the phase of which has been modulated with the video signal. The signal converter includes: a laser light source; a modulating section for modulating the phase of output light of the laser light source with the multichannel video signal and modulating the intensity of the output light with the microwave signal; and a light receiver for receiving the output light modulated by the modulating section and for outputting the microwave signal, the phase of which has been modulated with the multichannel video signal.

Abstract: An antibacterial compound wherein represents benzene ring, pyridine ring, pyrazine ring or 5-membered aromatic neterocycle (having one oxygen or sulfur atom as ring-constituting atom), there being no R4 where  represents 5-membered aromatic heterocycle; X and Y respectively represent hydrogen atom or CXY represents C═N—OR5 wherein R5 represents hydrogen atom, halo C1-C6 alkyl or C3-C7 cycloalkyl; R1 represents phenyl, furyl, thienyl, thiazolyl (which may be substituted by amino group), tetrazolyl or thiadiazolyl, R2, R3 and R4 respectively represent hydrogen atom, halogen, hydroxyl group, nitro, C1-C6 alkoxy, trifluoromethyl, isothiuronium C1-C6 alkyl, amino C1-C6 alkyl, halo C1-C6 alkyl, morpholino, piperidino or piperazinyl.